Get the Stockscreener App
52.13
0.75%
-0.3915
Biomarin Pharmaceutical Inc stock is traded at $52.13, with a volume of 112.59K.
It is down -0.75% in the last 24 hours and down -5.96% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$52.52
Open:
$52.17
24h Volume:
112.59K
Relative Volume:
0.05
Market Cap:
$10.00B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
19.38
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+0.51%
1M Performance:
-5.96%
6M Performance:
-16.01%
1Y Performance:
-21.07%
1-Day Range:
$51.86
$52.60
1-Week Range:
$51.00
$54.25
52-Week Range:
$51.00
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.08 | 10.09B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
415.01 | 107.10B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.17 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.93 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
829.88 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.59 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Using AI based signals to follow BioMarin Pharmaceutical Inc.July 2025 Action & Fast Entry and Exit Trade Plans - newser.com
How to monitor BioMarin Pharmaceutical Inc. with trend dashboardsBuy Signal & Growth Oriented Trade Recommendations - newser.com
Price-Driven Insight from (BMRN) for Rule-Based Strategy - news.stocktradersdaily.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervalued2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) - Insider Monkey
BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News - Yahoo Finance
What analysts say about BioMarin Pharmaceutical Inc stockStock Buyback Announcements & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Sanford C. Bernstein Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $88.00 - MarketBeat
Key resistance and support levels for BioMarin Pharmaceutical Inc.M&A Rumor & Real-Time Volume Trigger Notifications - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.Trend Reversal & Verified Technical Signals - newser.com
10 Stocks to Buy With Over 50% Upside Potential - Insider Monkey
Bernstein Maintains BioMarin Pharmaceutical (BMRN) Outperform Recommendation - Nasdaq
BioMarin Pharmaceutical Unleashes VOXZOGO Expansion—Is a Market Breakout Coming? - Smartkarma
Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight - GlobeNewswire Inc.
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecastsQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
Bernstein lowers BioMarin stock price target to $88 on growth concerns - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Position Increased by Plato Investment Management Ltd - MarketBeat
How to read the order book for BioMarin Pharmaceutical Inc.July 2025 Action & Target Return Focused Picks - newser.com
Eleva Capital SAS Invests $1.29 Million in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap by valuation metricsDollar Strength & Weekly Stock Performance Updates - newser.com
Keybank National Association OH Sells 19,707 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call - TradingView
Can BioMarin Pharmaceutical Inc. stock hit analyst price targets2025 Buyback Activity & Consistent Profit Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Day Trade & Fast Momentum Entry Tips - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
What is William Blair's Estimate for BMRN Q4 Earnings? - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 14,700 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetOptions Play & Weekly Return Optimization Plans - newser.com
Why BioMarin Pharmaceutical Inc. stock is in analyst buy zoneWeekly Trend Report & Safe Capital Growth Stock Tips - newser.com
Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as Shares Recover 3% After Prolonged Downtrend - Sahm
10 Best Beaten Down Growth Stocks to Buy According to Analysts - Insider Monkey
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Cantor Fitzgerald Has Negative View of BMRN FY2025 Earnings - MarketBeat
How currency fluctuations impact BioMarin Pharmaceutical Inc. stock2025 Technical Overview & Safe Swing Trade Setups - newser.com
Sentiment analysis tools applied to BioMarin Pharmaceutical Inc.Global Markets & AI Enhanced Trading Alerts - newser.com
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.80%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):